+91-8668442535

Painful Diabetic Neuropathy Drugs Market By Drug Type (Nucynta/Palexia, Lyrica, Cymbalta, Qutenza (8% Capsaicin patch), Tricyclic Antidepressants, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Anticonvulsants, Opioids, Pipeline Analysis) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

With a strong drug pipeline portfolio, the market for painful diabetic neuropathy drugs is expected to grow rapidly.

The global market for painful diabetic neuropathy (PDN) drugs accounted for US$ 4,811.8 million in 2017 and is expected to attain US$ 8,962.0 million by 2026, growing at a CAGR of 6.6% during the forecast period from 2018 to 2026. Of the various marketed drugs analyzed, Lyrica accounted for the maximum market share in 2017, while Qutenza will exhibit the fastest CAGR during the forecast period from 2018 to 2026. Lyrica and Cymbalta are the only medications recommended as first-line therapy for PDN, thus depicting dominance throughout the study period from 2016 to 2026. Along with the aforementioned products, Nucynta and Palexia are also approved for the treatment of PDN, thus contributing to the overall market. Along with the availability of approved drugs, the rising prevalence of diabetes and growing awareness of diabetic complications will further catalyze the market's growth.

The PDN drug market comprises an extensive drug pipeline portfolio with a prime focus on developing target-based therapy to reduce disease progression. VM202 (ViroMed Co. Ltd.) and Mirogabalin Besylate (Daiichi-Sankyo Co. Ltd.) are potential Phase III pipeline molecules whose positive results will ensure the PDN drugs market's profitability during the forecast period. This market provides multiple opportunities to new entrants with disease-modifying molecules, thus increasing the investment among market players in research activities.

The PDN drugs market encompasses a vast market outreach across various geographies owing to the rising prevalence of diabetes and diabetes-associated complications. North America accounted for the maximum market share in 2017, while Asia Pacific exhibited the fastest CAGR during the forecast period from 2018 to 2026. Diabetes prevalence and awareness, medication availability, and the presence of developed healthcare infrastructure in North America all contribute to market growth.

Market Synopsis

Lyrica has gained maximum market share and will continue with similar trends during the forecast period.

Based on drug type, Lyrica accounted for the highest market share of above 26% in 2017 and will continue its dominance throughout the forecast period from 2018 to 2026. Lyrica is the only marketed drug that has gained marketing approval from the Food and Drug Administration (FDA) of the U.S., the European Medical Agency (EMA), and the Pharmaceutical and Medical Device Agency (PMDA) of Japan. Lyrica is also recommended as the first line of therapy by the American Diabetes Association to treat PDN. These factors make Lyrica a dominant contributor to the overall growth of the market. Additionally, the recent approval of Lyrica CR (October 2017) by the U.S. FDA ensures the remunerative growth of this market segment. Qutenza accounts for the fastest CAGR during the forecast period from 2018 to 2026. Qutenza is approved so far only in Europe; further marketing approval across geographies and its formulation as an adhesive patch would increase the demand for the same upon approval. Qutenza comprises minimal patient discomfort when compared to the daily dosing of therapeutic agents, which is why it is projected to gain market attraction. However, the market share of existing approved products could be hampered by the penetration of pipeline molecules with target-based therapy.

North America demonstrated supremacy in 2017 and will maintain its dominance through 2026.

North America accounted for a major market share of more than 55% in 2017 and is projected to continue the trend throughout the forecast period. Diabetes and diabetes-related complications are the primary drivers of market growth in this region. Rapid commercialization of novel drugs, as well as ongoing investment by local manufacturers in developing target-based therapy, drive market growth. According to the Centers for Disease Control and Prevention (CDC), around 30.3 million individuals of all ages suffered from diabetes in 2015 in the U.S. Diabetes' high prevalence raises the risk of painful diabetic neuropathy, indicating potential market growth. Asia Pacific will exhibit the fastest CAGR during the forecast period from 2018 to 2026. Growing awareness of diabetes-associated complications, the availability of newer products, and investment by international players all contribute to the growth in this region.

The presence of an extensive pipeline portfolio indicates penetration by new industrial leaders during the forecast period.

The market for painful diabetic neuropathy drugs observes a competitive pool comprising off-label drug manufacturers, PDN-approved drug manufacturers, and new market entrants with promising pipeline portfolios. Pfizer, Inc. maintained its supremacy in 2017 owing to its product Lyrica, which is recommended as the first line of therapy and accounted for the maximum market share in 2017. Other industrial players, namely Grunenthal GmbH and Collegium Pharmaceutical, Inc., also contributed to the overall growth of this market. However, the approved drugs only provide a reduction in pain and do not cure the underlying cause. As a result, this market is witnessing an elaborative pipeline portfolio, with multiple market players conducting research activities in the development of target-based drugs or gene therapy. ViroMed's VM202, currently in Phase III, has exhibited positive results in providing long-term relief and modifying PDN progression. Its potential efficacy and reduced adverse effects make it a potential candidate for catalyzing market growth and would be a threat to the existing market players upon market penetration during the forecast period.

Periods of History and Forecast

This study report provides analysis for each segment during the period from 2016 to 2026, keeping 2017 as the base year. The CAGR for each segment is also estimated for the forecast period from 2018 to 2026.

Report Scope by Segments

The painful diabetic neuropathy drugs market report comprises an extensive analysis of the market's trends and dynamics along with a qualitative analysis of the global market. The report analyses the global market for drugs that treat painful diabetic neuropathy in-depth, segmenting the market by drug type and geography. The prime objective of publishing this study is to guide healthcare professionals and market leaders in decision-making and strategic initiatives in the painful diabetic neuropathy drugs market.

The current study report also comprises qualitative information pertaining to key market trends with respect to market drivers, restraints, and opportunities that would guide a thorough understanding of the overall painful diabetic neuropathy drugs market scenario. Furthermore, a graphic representation of the competitive landscape depicting the market positioning of key industrial players based on their product offerings and business strengths has been incorporated into this report. Key market leaders profiled in this report are Pfizer, Inc.; Grunenthal GmbH; Daiichi-Sankyo Company Limited; ViroMed Co., Ltd.; Collegium Pharmaceutical, Inc.; Eli Lilly and Company; Acorda Therapeutics, Inc.; Zydus Pharmaceuticals USA, Inc.; Mallinckrodt, Inc.; and Macleods Pharmaceuticals Ltd.

Frequently Asked Questions:

The market for Painful Diabetic Neuropathy Drugs Market is expected to reach US$ 11,506.3 Mn by 2026.

The Painful Diabetic Neuropathy Drugs Market is expected to see significant CAGR growth over the coming years, at 6.6%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Pfizer, Inc.; Grunenthal GmbH; Daiichi-Sankyo Company Limited; ViroMed Co., Ltd.; Collegium Pharmaceutical, Inc.; Eli Lilly and Company; Acorda Therapeutics, Inc.; Zydus Pharmaceuticals USA, Inc.; Mallinckrodt, Inc are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  May 2018
Category:  Pharmaceuticals
Report ID:   59180
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support